Acceleron Reports First Quarter 2020 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Acceleron Pharma (XLRN) Misses Q1 EPS by 9c
May 11, 2020 4:25 PM EDTAcceleron Pharma (NASDAQ: XLRN) reported Q1 EPS of ($0.95), $0.09 worse than the analyst estimate of ($0.86).
Acceleron is off to a strong start in 2020, propelled by one of the most eventful time periods in the Companys history, said Habib Dable, President and Chief Executive Officer of Acceleron. The breadth and depth of our hematology program has been on full display, owing to the publication... More
